Nano-liposomal berberine and vildagliptin combination: A novel therapeutic approach against oxidative stress, inflammation, autophagy dysregulation, and fibrosis in diabetic nephropathy

An important consequence of diabetes is diabetic nephropathy (DN), which could end up in end-stage renal failure and chronic kidney disease. Blood glucose control, reduction of inflammation, management of oxidative stress, enhancement of autophagy, and repair of renal injury and fibrosis are important strategies for the management of DN. This research examined the protective benefits of berberine hydrochloride liposomes (BHC-Lip) and/or vildagliptin (Vild) against DN in rats with high-fat diet/streptozotocin (HFD/STZ) were examined in this investigation. The rats were separated into four diabetic groups and a control group. These groups are T2DM, T2DM-BHC-Lip, T2DM-Vildagliptin (Vild), and T2DM-BHC-Lip-Vild groups. BHC-Lip or Vild treatment significantly restored antioxidant capacity, resulting in decreased MDA and elevated GPx, SOD, and GSH levels in renal tissues, with combined therapy producing the most powerful effect. The combined therapy significantly improved renal function biomarkers, including creatinine, urea, sodium, and potassium levels, restoring them to nearly control levels. Furthermore, BHC-Lip or Vild treatments markedly reduced serum inflammatory cytokines and upregulated autophagy-related gene expression, with increased expression of Beclin-1 and LC3, and decreased expression of PI3K/Akt/mTOR/P62 signaling. In contrast, combination therapy produced superior autophagic activation and suppression of pro-inflammatory pathways. Furthermore, there was a noticeable improvement in kidney damage and fibrosis indicators (nephrin and higher nestin, desmin, and vimentin), especially those receiving combined treatment. Histopathological examination supported these findings, showing significant improvement in kidney architecture. Together, our findings show that Vild and BHC-Lip work in concert to prevent DN through lowering oxidative stress and inflammation, boosting autophagy, and reducing renal structural damage.

Authors

Institutions

Publication Details

Journal
Tissue and Cell
Published
2026-02-03
DOI
https://doi.org/10.1016/j.tice.2026.103355
Primary Topic
Berberine and alkaloids research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Nano-liposomal berberine and vildagliptin combination: A novel therapeutic approach against oxidative stress, inflammation, autophagy dysregulation, and fibrosis in diabetic nephropathy

Mahmoud Mostafa, Mahran Mohamed Abd El-Emam, Tarek Khamis, Mona I. Abdel Ati et al.
Tissue and Cell
Berberine and alkaloids research
article

Nano-liposomal berberine and vildagliptin combination: A novel therapeutic approach against oxidative stress, inflammation, autophagy dysregulation, and fibrosis in diabetic nephropathy

Mahmoud Mostafa, Mahran Mohamed Abd El-Emam, Tarek Khamis, Mona I. Abdel Ati, Mohamed Mohamed Soliman, Safaa I. Khater, Ola Ali, Shatha B. Albattal, Rawan Altalhi, Areej A. Eskandrani
article en

Abstract

An important consequence of diabetes is diabetic nephropathy (DN), which could end up in end-stage renal failure and chronic kidney disease. Blood glucose control, reduction of inflammation, management of oxidative stress, enhancement of autophagy, and repair of renal injury and fibrosis are important strategies for the management of DN. This research examined the protective benefits of berberine hydrochloride liposomes (BHC-Lip) and/or vildagliptin (Vild) against DN in rats with high-fat diet/streptozotocin (HFD/STZ) were examined in this investigation. The rats were separated into four diabetic groups and a control group. These groups are T2DM, T2DM-BHC-Lip, T2DM-Vildagliptin (Vild), and T2DM-BHC-Lip-Vild groups. BHC-Lip or Vild treatment significantly restored antioxidant capacity, resulting in decreased MDA and elevated GPx, SOD, and GSH levels in renal tissues, with combined therapy producing the most powerful effect. The combined therapy significantly improved renal function biomarkers, including creatinine, urea, sodium, and potassium levels, restoring them to nearly control levels. Furthermore, BHC-Lip or Vild treatments markedly reduced serum inflammatory cytokines and upregulated autophagy-related gene expression, with increased expression of Beclin-1 and LC3, and decreased expression of PI3K/Akt/mTOR/P62 signaling. In contrast, combination therapy produced superior autophagic activation and suppression of pro-inflammatory pathways. Furthermore, there was a noticeable improvement in kidney damage and fibrosis indicators (nephrin and higher nestin, desmin, and vimentin), especially those receiving combined treatment. Histopathological examination supported these findings, showing significant improvement in kidney architecture. Together, our findings show that Vild and BHC-Lip work in concert to prevent DN through lowering oxidative stress and inflammation, boosting autophagy, and reducing renal structural damage.

Tissue and CellVol. 100
Alfaisal University (SA), Taif University (SA), Zagazig University (EG), Taibah University (SA), University of Jeddah (SA), Dar Al Uloom University (SA), Almaarefa University, Minia University (EG)
Good health and well-being
Openalex Percentile: Top 69%
Berberine and alkaloids research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.